Endocrine-Related Cancer

Papers
(The TQCC of Endocrine-Related Cancer is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Acknowledgement to reviewers104
Survival following resection of 10,244 lung neuroendocrine tumours: a population study92
Refining long-term surveillance requirements in patients with differentiated thyroid cancer62
ERRATUM: Roles of the HOXA10 gene during castrate-resistant prostate cancer progression53
Chemokines with CXC motif and their receptors in neuroendocrine neoplasms49
Clinical presentation of bone metastases in neuroendocrine tumors: a retrospective cohort study46
Defining aging-associated factors that increase susceptibility to prostate cancer45
Acknowledgement to reviewers44
Prognostic of recurrence and survival in poorly differentiated thyroid cancer33
Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells33
Targeting growth hormone in cancer: future perspectives32
Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients32
Сytotoxic T lymphocyte-associated protein 4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas31
Identifying metastatic renal cell carcinoma in thyroid fine-needle aspirates by molecular testing28
Update on the genetics of paragangliomas27
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs27
Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications27
Peptide receptor radionuclide therapy in malignant insulinoma26
Differential activity of specific inhibitors of transcription regulating cyclin-dependent kinases in thyroid cancer cells26
FAM64A contributes to ovarian cancer proliferation and metastasis by suppressing TWIST1 ubiquitination and degradation25
CORRIGENDUM: GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts24
The genetic changes in 11p15.5-related pheochromocytomas and paragangliomas24
Metabolically active brown adipose tissue in PPGL: an observational cohort study23
Impact of sex hormones on development and progression in NEN: a new therapeutic target?23
MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells23
Genistein induces endocrine resistance in human breast cancer by suppressing H3K27 trimethylation22
CCL2 expression predicts clinical outcomes and regulates E-cadherin and angiogenesis in pituitary tumours21
Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet21
Two miRNAs enriched in plasma extracellular vesicles are potential biomarkers for thyroid cancer20
Rising incidence of follicular thyroid carcinoma and oncocytic carcinoma of the thyroid in Australia18
Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma18
Whole-exome sequencing of rectal neuroendocrine tumors17
lncRNA DIRC3 regulates invasiveness and insulin-like growth factor signaling in thyroid cancer cells17
Gender-affirming care and endocrine-related cancers16
Long-term survival of metastatic small intestine neuroendocrine tumors: a meta-analysis15
RET signalling in the pituitary: a double-edged sword for differentiation, apoptosis and therapeutic strategies in acromegaly15
Bone metastasis in endocrine-related cancer: unravelling invasion and destruction15
Effect of TSH levels during active surveillance of PTMC according to age15
Distortion in transmission of pathogenic SDHB- and SDHD-mutated alleles from parent to offspring15
Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective15
ThyroidPrint®: clinical utility for indeterminate thyroid cytology14
Immunotherapy for endocrine tumours: a clinician’s perspective14
Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study14
Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen14
Genetic variants of glucose metabolism and exposure to smoking in African American breast cancer13
Steroid profile in patients with breast cancer and in mice treated with mifepristone13
Embryonic stem cell factor FOXD3 (Genesis) defects in gastrointestinal stromal tumors13
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms13
Exploring stem cell biology in pituitary tumors and derived organoids12
Inhibition of GATA2 in prostate cancer by a clinically available small molecule12
The role of the tumor microenvironment in papillary thyroid microcarcinoma nodal metastasis12
Clinical features of plurihormonal pituitary adenoma subtypes12
Acknowledgement to reviewers12
From bench to bedside in the sella: translational developments in pituitary tumour genetics12
Exploring the tumor suppressor role of RIN1 in familial thyroid carcinoma12
Acknowledgement to reviewers12
Genetic disorders and insulinoma/glucagonoma11
Plasma metabolomics for the preoperative diagnosis of parathyroid carcinoma11
Two distinct classes of thymic tumors in patients with MEN1 show LOH at the MEN1 locus11
Subgroup analysis of steadily increased trends in medullary thyroid carcinoma incidence and mortality in the USA, 2000–2020: a population-based retrospective cohort study11
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review11
Ampullary composite gangliocytoma/neuroma and neuroendocrine tumor management11
Mammary gland development and EDC-driven cancer susceptibility in mesenchymal ERα-knockout mice11
Systems biology successes and areas for opportunity in prostate cancer11
New therapeutic opportunities for women with low-grade serous ovarian cancer11
In vivo and in vitro analysis of functional effects of the SDHD H50R variant11
Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity10
Insights on epidemiology, morbidity and mortality of Cushing’s disease in Northern Ireland10
Clinical Outcomes of Malignant Pleural Effusion in Patients with Lung Metastases from Differentiated Thyroid Cancer10
Spectrum and carcinogenic properties of thyroglobulin gene fusions in thyroid10
Diagnosis and management of parathyroid carcinoma: a state-of-the-art review10
Cancer in Ecuadorian subjects with Laron syndrome (ELS)10
Sexual dimorphism in thyroid cancer: evidence from preclinical studies9
International symposium on pheochromocytoma: an event of dedicated healthcare professionals and researchers striving for better patient outcomes9
miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L29
Non-pituitary GH regulation of the tissue microenvironment9
COL12A1 as a prognostic biomarker links immunotherapy response in breast cancer9
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal9
Genetic variants and down-regulation of CACNA1H in pheochromocytoma9
Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane9
Cutoff value of thyroglobulin in needle aspirates for screening neck masses of thyroid carcinoma9
Deiodinases in thyroid tumorigenesis9
In memoriam: Charis Eng MD PhD (1962–2024)9
Reduced MHC class II expression in medullary thyroid cancer identifies patients with poor prognosis9
Surrogate molecular classification of LAR breast cancer in routine workflow9
Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort9
Beyond the three P’s: adrenal involvement in MEN19
Mitochondrial dynamics and oxidative phosphorylation as critical targets in cancer8
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma8
Precocious puberty due to intracranial germ cell tumors: a case–control study8
Genotype-specific development of MEN 2 constituent components in 683 RET carriers8
The science behind the relations among cancer, height, growth patterns, and growth hormone axis8
Limited value of genetic profiling in guiding radioiodine therapy for metastatic differentiated thyroid cancer8
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms8
Promoter mutation-independent TERT expression is related to the immune-enriched milieu in papillary thyroid cancer8
Targeting anti-apoptosis as a therapeutic strategy in neuroendocrine neoplasms8
Tumor suppressor gene ARMC5 controls adrenal redox state through NRF1 turnover8
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading8
Management of high-grade neuroendocrine neoplasms: impact of functional imaging8
Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center8
MicroRNAs as regulators of tumor metabolism8
0.095902919769287